antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-200Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR PRACTITIONERSКлиническая фармакокинетика таблеток парааминосалициловой кислотыClinical Pharmacokinetics of Paraaminosalicylic Acid TabletsМирошниченкоИ. И.MiroshnichenkoI. I.noemail@neicon.ruСоколоваГ. Б.SokolovaG. B.noemail@neicon.ruМохиреваЛ. В.MokhirevaL. V.noemail@neicon.ruНЦПЗ РАМН; НИИ фтизиатрии и пульмонологии ММА им И.М. Сеченова, Москва; ОАО «АКРИХИН», МоскваРоссияScientific Centre of Mental Health, Russian Academy of Medical Sciences, Moscow; Research Institute of Phthisiology and Pulmonologyry, I.M. Sechenov Moscow Medical Academy, Moscow; Akrikhin Co., MoscowRussian Federation200913052020541-22024Copyright © Мирошниченко И.И., Соколова Г.Б., Мохирева Л.В., 20202020Мирошниченко И.И., Соколова Г.Б., Мохирева Л.В.Miroshnichenko I.I., Sokolova G.B., Mokhireva L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/200

Проведено изучение фармакокинетических параметров препарата ПАСК-Акри, производимого фирмой ОАО «АКРИХИН», (Россия) и выпускаемого в виде таблеток, покрытых оболочкой, содержащих ПАСК в виде дигидрата соли натрия в количестве 1000 мг. Здоровые добровольцы принимали однократно внутрь 6, 9 или 12 таблеток по 1 г ПАСК-Акри, через 7 дней добровольцы принимали ПАСК-Акри в другой дозировке. Пробы крови отбирались через 0,25; 0,5; 0,75, 1, 2, 4, 6, 8 и 10 часов после введения. Концентрации ПАСК в сыворотке крови добровольцев определяли методом ВЭЖХ. Проведенные исследования позволят оптимизировать дозирование ПАСК для достижения эффективной противотуберкулезной терапии

Pharmacokinetic parameters of PAS-Akri coated tablets (Akrikhin, Russia) were investigated. The tablets contain paraaminosalicylic acid (PAS) as sodium dihydrate in an amount of 1000 mg. The single oral dose of the drug for healthy volunteers in the trial was 6, 9 or 12 tablets. In 7 days the dosage was changed. The blood samples were collected 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 10 hours after the drug administration. The PAS serum levels were determined with HPLC. The trials will allow to optimize the dosing of PAS for providing efficient antituberculosis therapy.

клиническая фармакокинетикапротивотуберкулезные препаратыпарааминосалициловая кислотыдоброволъцыclinical pharmacokineticsantituberculosis drugsparaaminosalicylic acidvolunteersReferencesIseman M.D. Tuberculosis therapy: past, present and future. // Eur. Respir. J 2002; 36: 87-94.Iseman M.D. Tuberculosis therapy: past, present and future. // Eur. Respir. J 2002; 36: 87-94.Wilson J.W., Kelkar P., Frigas E. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis. // Int J Tuberc Lung Dis 2003; 7 (5): 493-497.Wilson J.W., Kelkar P., Frigas E. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis. // Int J Tuberc Lung Dis 2003; 7 (5): 493-497.Glazko A.J. Early adventures in drug metabolism: 2. The absorption of drugs. // Ther Drug Monit. 1987; 9 (2): 180-189.Glazko A.J. Early adventures in drug metabolism: 2. The absorption of drugs. // Ther Drug Monit. 1987; 9 (2): 180-189.Hughes N.C., Janezic S.A., McQueen K.L. et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in vivo and in vitro probe. Pharmacogenetics. 1998; 8 (1): 55-66.Hughes N.C., Janezic S.A., McQueen K.L. et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in vivo and in vitro probe. Pharmacogenetics. 1998; 8 (1): 55-66.Peloquin C.A., Zhu M., Adam R.D., Singleton M.D., Nix D.E. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. // Ann Pharmacother 2001; 35: 1332-1338.Peloquin C.A., Zhu M., Adam R.D., Singleton M.D., Nix D.E. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. // Ann Pharmacother 2001; 35: 1332-1338.Vasbinder E., Van der Weken G., Vander Heyden Y. et al. Quantitative determination of p-aminosalicylic acid and its degradation product m-aminophenol in pellets by ion-pair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e column. // Biomed Chromatogr 2004; 18 (1): 55-63.Vasbinder E., Van der Weken G., Vander Heyden Y. et al. Quantitative determination of p-aminosalicylic acid and its degradation product m-aminophenol in pellets by ion-pair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e column. // Biomed Chromatogr 2004; 18 (1): 55-63.Мирошниченко И.И. Основы фармакокинетики. М: ГЭОТАР-МЕД 2002. 192.Мирошниченко И.И. Основы фармакокинетики. М: ГЭОТАР-МЕД 2002. 192.Laub P.B., Gallo J.M. NCOMP a Windows-based computer program for noncompartmental analysis of pharmacokinetic data. // J. Pharmaceut. Sci. 1996; 85: 4: 393-395.Laub P.B., Gallo J.M. NCOMP a Windows-based computer program for noncompartmental analysis of pharmacokinetic data. // J. Pharmaceut. Sci. 1996; 85: 4: 393-395.Schlatter J., Di Blasi-Bouvet S., Raynaud F., Cisternino S. Population pharmacokinetics of methotrexate in the guinea pig. // Cell Mol Biol 1999. 30; 3: 363-368.Schlatter J., Di Blasi-Bouvet S., Raynaud F., Cisternino S. Population pharmacokinetics of methotrexate in the guinea pig. // Cell Mol Biol 1999. 30; 3: 363-368.

The authors declare that there are no conflicts of interest present.